Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial

Obesity

Volumn 24, Issue 7, 2016, Pages 1454-1463

  Arzola Paniagua, María Angélica ^a   García Salgado López, Enrique Raúl ^a   Calvo Vargas, Cesar G ^b   Guevara Cruz, Martha ^c  

^a Instituto Biosen AC   (Mexico)

^b Centro de Diseño y Planeación en Investigación Médica S C   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; LEPTIN; PLACEBO; RESVERATROL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENERGY CONSUMPTION; FAT MASS; FEMALE; FOOD INTAKE; HUMAN; MALE; MIDDLE AGED; MONOTHERAPY; NAUSEA; OBESITY; RANDOMIZED CONTROLLED TRIAL; RECALL; STEATORRHEA; TREATMENT DURATION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; YOUNG ADULT;

EID: 84976624184     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21523     Document Type: Article

References (37)

1. Fuentes E, Fuentes F, Vilahur G, Badimon L, Palomo I. Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediat Inflamm 2013;2013:136584.
2. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992;55:309S-313S.
3. Aldekhail NM, Logue J, McLoone P, Morrison DS. Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Obes Rev 2015;16:1071-1080.
4. Gonzalez-Castejon M, Rodriguez-Casado A. Dietary phytochemicals and their potential effects on obesity: a review. Pharmacol Res 2011;64:438-455.
5. Fremont L. Biological effects of resveratrol. Life Sci 2000;66:663-673.
6. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 2007;104:7217-7222.
7. Bitterman JL, Chung JH. Metabolic effects of resveratrol: addressing the controversies. Cell Mol Life Sci 2015;72:1473-1488.
8. Pereira S, Park E, Moore J, et al. Resveratrol prevents insulin resistance caused by short-term elevation of free fatty acids in vivo. Appl Physiol Nutr Metab 2015;40:1129-1136.
9. Wang S, Liang X, Yang Q, et al. Resveratrol induces brown-like adipocyte formation in white fat through activation of AMP-activated protein kinase (AMPK) alpha1. Int J Obes (Lond) 2015;39:967-976.
10. Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009;77:1053-1063.
11. Gomez-Zorita S, Fernandez-Quintela A, Macarulla MT, et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr 2012;107:202-210.
12. Liu M, Liu F. Up- and down-regulation of adiponectin expression and multimerization: mechanisms and therapeutic implication. Biochimie 2012;94:2126-2130.
13. Derdemezis CS, Kiortsis DN, Tsimihodimos V, et al. Effect of plant polyphenols on adipokine secretion from human SGBS adipocytes. Biochem Res Int 2011;2011:285618.
14. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011;14:612-622.
15. Tome-Carneiro J, Larrosa M, Yanez-Gascon MJ, et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res 2013;72:69-82.
16. Wicklow B, Wittmeier K, T' Jong, et al. Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol. Biochem Cell Biol 2014;1-9.
17. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 2011;21:851-856.
18. Scapagnini G, Davinelli S, Kaneko T, et al. Dose response biology of resveratrol in obesity. J Cell Commun Signal 2014;8:385-391.
19. Nishimura Y, Sasagawa S, Ariyoshi M, et al. Systems pharmacology of adiposity reveals inhibition of EP300 as a common therapeutic mechanism of caloric restriction and resveratrol for obesity. Front Pharmacol 2015;6:199.
20. de Ligt M, Timmers S, Schrauwen P. Resveratrol and obesity: can resveratrol relieve metabolic disturbances? Biochim Biophys Acta 2015;1852:1137-1144.
21. Zagotta I, Dimova EY, Debatin KM, Wabitsch M, Kietzmann T, Fischer-Posovszky P. Obesity and inflammation: reduced cytokine expression due to resveratrol in a human in vitro model of inflamed adipose tissue. Front Pharmacol 2015;6:79.
22. National Cholesterol Education Program (NCEP) Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
23. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 2005;13:322-327.
24. Lohman TG, Roche AF, Mantorrel R. Anthropometric Standardization Reference Manual. Human Kinetics Books: Champaign, IL; 1988.
25. Poston WS, Haddock CK, Pinkston MM, et al. Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat. J Intern Med 2006;260:388-398.
26. Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012;148:421-433.
27. Wang S, Moustaid-Moussa N, Chen L, et al. Novel insights of dietary polyphenols and obesity. J Nutr Biochem 2014;25:1-18.
28. Lau DC, Teoh H. Current and emerging pharmacotherapies for weight management in prediabetes and diabetes. Can J Diabetes39(Suppl 5):S134-S141.
29. Phelan S, Wadden TA, Berkowitz RI, et al. Impact of weight loss on the metabolic syndrome. Int J Obes (Lond) 2007;31:1442-1448.
30. Phillips CM, Tierney AC, Perez-Martinez P, et al. Obesity and body fat classification in the metabolic syndrome: impact on cardiometabolic risk metabotype. Obesity (Silver Spring) 2013;21:E154-E161.
31. Lima MM, Pareja JC, Alegre SM, et al. Visceral fat resection in humans: effect on insulin sensitivity, beta-cell function, adipokines, and inflammatory markers. Obesity (Silver Spring) 2013;21:E182-E189.
32. Kappelle PJ, Dullaart RP, van Beek AP, Hillege HL, Wolffenbuttel BH. The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: a prospective nested case-control study. Eur J Intern Med 2012;23:755-759.
33. Satoh N, Naruse M, Usui T, et al. Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care 2004;27:2488-2490.
34. Karakas M, Zierer A, Herder C, et al. Leptin, adiponectin, their ratio and risk of coronary heart disease: results from the MONICA/KORA Augsburg Study 1984-2002. Atherosclerosis 2010;209:220-225.
35. Rathbone CR, Booth FW, Lees SJ. Sirt1 increases skeletal muscle precursor cell proliferation. Eur J Cell Biol 2009;88:35-44.
36. Wadden TA, Butryn ML, Byrne KJ. Efficacy of lifestyle modification for long-term weight control. Obes Res 2004;12(Suppl):151S-162S.
37. Bray GA. Why do we need drugs to treat the patient with obesity? Obesity (Silver Spring) 21:893-899.